Logo image of LPCN

LIPOCINE INC (LPCN) Stock Fundamental Analysis

NASDAQ:LPCN - Nasdaq - US53630X2036 - Common Stock - Currency: USD

2.96  -0.05 (-1.66%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to LPCN. LPCN was compared to 193 industry peers in the Pharmaceuticals industry. LPCN has a great financial health rating, but its profitability evaluates not so good. LPCN shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LPCN was profitable.
In the past year LPCN has reported a negative cash flow from operations.
In the past 5 years LPCN reported 4 times negative net income.
In the past 5 years LPCN always reported negative operating cash flow.
LPCN Yearly Net Income VS EBIT VS OCF VS FCFLPCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

LPCN has a Return On Assets (-26.20%) which is comparable to the rest of the industry.
LPCN has a Return On Equity of -27.97%. This is in the better half of the industry: LPCN outperforms 62.69% of its industry peers.
Industry RankSector Rank
ROA -26.2%
ROE -27.97%
ROIC N/A
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
LPCN Yearly ROA, ROE, ROICLPCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LPCN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LPCN Yearly Profit, Operating, Gross MarginsLPCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

LPCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LPCN has more shares outstanding
Compared to 5 years ago, LPCN has more shares outstanding
There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LPCN Yearly Shares OutstandingLPCN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
LPCN Yearly Total Debt VS Total AssetsLPCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -6.08, we must say that LPCN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of LPCN (-6.08) is worse than 61.66% of its industry peers.
There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.08
ROIC/WACCN/A
WACC10.11%
LPCN Yearly LT Debt VS Equity VS FCFLPCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

LPCN has a Current Ratio of 15.64. This indicates that LPCN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LPCN (15.64) is better than 88.60% of its industry peers.
LPCN has a Quick Ratio of 15.64. This indicates that LPCN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 15.64, LPCN belongs to the top of the industry, outperforming 88.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.64
Quick Ratio 15.64
LPCN Yearly Current Assets VS Current LiabilitesLPCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 143.13% over the past year.
Measured over the past years, LPCN shows a very strong growth in Earnings Per Share. The EPS has been growing by 213.46% on average per year.
The Revenue has grown by 492.81% in the past year. This is a very strong growth!
Measured over the past years, LPCN shows a very strong growth in Revenue. The Revenue has been growing by 133.89% on average per year.
EPS 1Y (TTM)143.13%
EPS 3Y213.46%
EPS 5YN/A
EPS Q2Q%28.07%
Revenue 1Y (TTM)492.81%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%595.55%

3.2 Future

Based on estimates for the next years, LPCN will show a very negative growth in Earnings Per Share. The EPS will decrease by -39.74% on average per year.
LPCN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.92% yearly.
EPS Next Y-217.56%
EPS Next 2Y-74.26%
EPS Next 3Y-39.74%
EPS Next 5YN/A
Revenue Next Year-92.26%
Revenue Next 2Y-76.71%
Revenue Next 3Y-13.85%
Revenue Next 5Y37.92%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
LPCN Yearly Revenue VS EstimatesLPCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 20M 40M 60M 80M
LPCN Yearly EPS VS EstimatesLPCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15 -20 -25

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 4.29, the valuation of LPCN can be described as very cheap.
Based on the Price/Earnings ratio, LPCN is valued cheaper than 96.89% of the companies in the same industry.
LPCN is valuated cheaply when we compare the Price/Earnings ratio to 26.85, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for LPCN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 4.29
Fwd PE N/A
LPCN Price Earnings VS Forward Price EarningsLPCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LPCN Per share dataLPCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as LPCN's earnings are expected to decrease with -39.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-74.26%
EPS Next 3Y-39.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LPCN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIPOCINE INC

NASDAQ:LPCN (8/19/2025, 8:02:10 PM)

2.96

-0.05 (-1.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners9.73%
Inst Owner Change2.1%
Ins Owners2.95%
Ins Owner Change0%
Market Cap15.84M
Analysts82.5
Price Target7.52 (154.05%)
Short Float %1.9%
Short Ratio2.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)278.92%
Min EPS beat(2)1.96%
Max EPS beat(2)555.88%
EPS beat(4)4
Avg EPS beat(4)150.83%
Min EPS beat(4)1.96%
Max EPS beat(4)555.88%
EPS beat(8)6
Avg EPS beat(8)87.37%
EPS beat(12)9
Avg EPS beat(12)56.86%
EPS beat(16)12
Avg EPS beat(16)139.3%
Revenue beat(2)1
Avg Revenue beat(2)-21.58%
Min Revenue beat(2)-74.1%
Max Revenue beat(2)30.95%
Revenue beat(4)1
Avg Revenue beat(4)-53.22%
Min Revenue beat(4)-100%
Max Revenue beat(4)30.95%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.56%
EPS NY rev (1m)0%
EPS NY rev (3m)4.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-38.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-46.91%
Valuation
Industry RankSector Rank
PE 4.29
Fwd PE N/A
P/S 4.31
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)0.69
EY23.31%
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-1.06
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0.69
BVpS3.59
TBVpS3.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.2%
ROE -27.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.64
Quick Ratio 15.64
Altman-Z -6.08
F-Score3
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)521.74%
Cap/Depr(5y)N/A
Cap/Sales(3y)9.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)143.13%
EPS 3Y213.46%
EPS 5YN/A
EPS Q2Q%28.07%
EPS Next Y-217.56%
EPS Next 2Y-74.26%
EPS Next 3Y-39.74%
EPS Next 5YN/A
Revenue 1Y (TTM)492.81%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%595.55%
Revenue Next Year-92.26%
Revenue Next 2Y-76.71%
Revenue Next 3Y-13.85%
Revenue Next 5Y37.92%
EBIT growth 1Y37.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.39%
OCF growth 3YN/A
OCF growth 5YN/A